Cargando…

The clinical effects of probiotics for inflammatory bowel disease: A meta-analysis

BACKGROUND: As the exact pathogenesis of inflammatory bowel disease (IBD) is not known, there is increasing evidence of clinical trials and animal models that indicate the beneficial effects of probiotics. METHODS: Multiple databases were adopted to search for the relevant studies involving the comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Kai, Tong, Xin, Wang, Rong, Song, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319782/
https://www.ncbi.nlm.nih.gov/pubmed/30572537
http://dx.doi.org/10.1097/MD.0000000000013792
_version_ 1783385124500406272
author Jia, Kai
Tong, Xin
Wang, Rong
Song, Xin
author_facet Jia, Kai
Tong, Xin
Wang, Rong
Song, Xin
author_sort Jia, Kai
collection PubMed
description BACKGROUND: As the exact pathogenesis of inflammatory bowel disease (IBD) is not known, there is increasing evidence of clinical trials and animal models that indicate the beneficial effects of probiotics. METHODS: Multiple databases were adopted to search for the relevant studies involving the comparison between probiotics and control groups. Review Manager 5.0 was used to assess the efficacy among included articles. Risk of bias for the articles included was also conducted. RESULTS: Finally, 10 studies eventually met the inclusion criteria and 1049 patients were included. The meta-analyses showed that no significant differences of remission, relapse, and complication rate between Escherichia coli Nissle 1917 and mesalazine groups (RR = 0.94, 95%CI [0.86, 1.03], P = .21; RR = 1.04, 95%CI [0.82, 1.31], P = .77; RR = 1.12, 95%CI [0.86, 1.47], P = .39, respectively). Despite the fact that no significant differences of remission, relapse, and complication rate were observed in overall meta-analysis results between probiotics and placebo group, the subgroup analyses suggested that VSL#3 presented a higher remission rate and lower relapse rate (RR = 1.67, 95%CI [1.06, 2.63], P = .03; RR = 0.29, 95%CI [0.10, 0.83], P = .02, respectively). CONCLUSION: Some types of probiotics, such as E coli Nissle 1917 and VSL#3, could be used as alternative therapy for patients with IBD.
format Online
Article
Text
id pubmed-6319782
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-63197822019-01-24 The clinical effects of probiotics for inflammatory bowel disease: A meta-analysis Jia, Kai Tong, Xin Wang, Rong Song, Xin Medicine (Baltimore) Research Article BACKGROUND: As the exact pathogenesis of inflammatory bowel disease (IBD) is not known, there is increasing evidence of clinical trials and animal models that indicate the beneficial effects of probiotics. METHODS: Multiple databases were adopted to search for the relevant studies involving the comparison between probiotics and control groups. Review Manager 5.0 was used to assess the efficacy among included articles. Risk of bias for the articles included was also conducted. RESULTS: Finally, 10 studies eventually met the inclusion criteria and 1049 patients were included. The meta-analyses showed that no significant differences of remission, relapse, and complication rate between Escherichia coli Nissle 1917 and mesalazine groups (RR = 0.94, 95%CI [0.86, 1.03], P = .21; RR = 1.04, 95%CI [0.82, 1.31], P = .77; RR = 1.12, 95%CI [0.86, 1.47], P = .39, respectively). Despite the fact that no significant differences of remission, relapse, and complication rate were observed in overall meta-analysis results between probiotics and placebo group, the subgroup analyses suggested that VSL#3 presented a higher remission rate and lower relapse rate (RR = 1.67, 95%CI [1.06, 2.63], P = .03; RR = 0.29, 95%CI [0.10, 0.83], P = .02, respectively). CONCLUSION: Some types of probiotics, such as E coli Nissle 1917 and VSL#3, could be used as alternative therapy for patients with IBD. Wolters Kluwer Health 2018-12-21 /pmc/articles/PMC6319782/ /pubmed/30572537 http://dx.doi.org/10.1097/MD.0000000000013792 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle Research Article
Jia, Kai
Tong, Xin
Wang, Rong
Song, Xin
The clinical effects of probiotics for inflammatory bowel disease: A meta-analysis
title The clinical effects of probiotics for inflammatory bowel disease: A meta-analysis
title_full The clinical effects of probiotics for inflammatory bowel disease: A meta-analysis
title_fullStr The clinical effects of probiotics for inflammatory bowel disease: A meta-analysis
title_full_unstemmed The clinical effects of probiotics for inflammatory bowel disease: A meta-analysis
title_short The clinical effects of probiotics for inflammatory bowel disease: A meta-analysis
title_sort clinical effects of probiotics for inflammatory bowel disease: a meta-analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319782/
https://www.ncbi.nlm.nih.gov/pubmed/30572537
http://dx.doi.org/10.1097/MD.0000000000013792
work_keys_str_mv AT jiakai theclinicaleffectsofprobioticsforinflammatoryboweldiseaseametaanalysis
AT tongxin theclinicaleffectsofprobioticsforinflammatoryboweldiseaseametaanalysis
AT wangrong theclinicaleffectsofprobioticsforinflammatoryboweldiseaseametaanalysis
AT songxin theclinicaleffectsofprobioticsforinflammatoryboweldiseaseametaanalysis
AT jiakai clinicaleffectsofprobioticsforinflammatoryboweldiseaseametaanalysis
AT tongxin clinicaleffectsofprobioticsforinflammatoryboweldiseaseametaanalysis
AT wangrong clinicaleffectsofprobioticsforinflammatoryboweldiseaseametaanalysis
AT songxin clinicaleffectsofprobioticsforinflammatoryboweldiseaseametaanalysis